Based on predicted or known modulation of CYP3A4 and P-gp, DOAC should be cautiously used in case of co-treatment with many anti-tumor drugs, such as doxorubicin, abiraterone, enzalutamide, imatinib, and sunitinib [38]. Here, CYP3A4 is linked to neoplasm.